New model for in vivo studies of pharmacological interventions with endogenous fibrinolysis: Effects of thrombin inhibitors

Seminars in Thrombosis and Hemostasis

Volumn 22, Issue 4, 1996, Pages 335-342

  Lenfors, Susanne ^a   Gustafsson, David ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Ancrod; Batroxobin; Fibrinolysis; Thrombin; Thrombin inhibitors

Indexed keywords

ACETYL DEXTRO PHENYLALANYLPROLYLBOROARGININE; ANCROD; ARGATROBAN; BATROXOBIN; FIBRINOGEN; IODINE 125; PLASMIN; THROMBIN INHIBITOR; TRANEXAMIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FIBRINOLYSIS; INTRAVENOUS DRUG ADMINISTRATION; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0029831492     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-999028     Document Type: Article

References (16)

1. 131I. J Clin Invest 45:1202-1212, 1966.
2. Markwardt F, B Kaiser, M Richter: Haemostypic effects of batroxobin with regard to hirudin treatment. Thromb Res 68:475-482, 1992.
3. Silberman S, EV Potter, HC Kwaan: Effects of arvin in mice. Exp Mol Pathol 14:67-74, 1971.
4. Klöcking H-P, F Markwardt, J Güttner: On the mechanism of batroxobin-induced fibrinolysis. Pharmazie 7:504-505, 1989.
5. Krishnamurti C, CF Barr, MA Hassett, GD Young, BM Alving: Plasminogen activator inhibitor: A regulator of ancrod-induced fibrin deposition in rabbits. Blood 69:798-803, 1987.
6. Lenfors S, L Marberg, S Wikström, U Jonsson, AW Eriksson, D Gustafsson: A new rat model of arterial thrombosis with a platelet-rich head and an erythrocyte-rich tail: Thrombolysis experiments with specific thrombin inhibition. Blood Coagul Fibrinolysis 4:263-271, 1993.
7. Åstedt B: Clinical pharmacology of tranexamic acid. Scand J Gastroenterol Suppl 137:22-25, 1987.
8. 2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]-L-arginyl)]-2- piperidinecarboxylic acid. Biochemistry 23:85-90, 1984.
9. Kettner C, L Mersinger, R Knabb: The selective inhibition of thrombin by peptides of boroarginine. J Biol Chem 265:18289-18297, 1990.
10. Cannon CP, CH McCabe, TD Henry, MJ Schweiger, RS Gibson, HS Mueller, RC Becker, NS Kleiman, JM Haugland, JL Anderson, BL Sharaf, SJ Edwards, WJ Rogers, DO Williams, E Baunwald: A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 23:993-1003, 1994.
11. Lidón RM, P Théroux, J Lespérance, B Adelman, R Bonan, D Duval, J Lévesque: A pilot, early angiographic patency study using a direct thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Circulation 89:1567-1572, 1994.
12. Ewart MR, MWC Hatton, JM Basford, KS Dodgson: The proteolytic action of arvin on human fibrinogen. Biochem J 118:603-609, 1970.
13. Pirkle H, K Stocker: Thrombin-like enzymes from snake venoms: An inventory. Thromb Haemostas 65:444-450, 1991.
14. Pizzo SV, ML Schwartz, RL Hill, PA McKee: Mechanism of ancrod anticoagulation. J Clin Invest 51:2841-2850, 1972.
15. Barlow GH, WH Holleman, L Lorand: The action of arvin on fibrin stabilizing factor (Factor XIII). Chem Pathol Pharmacol 1:39-42, 1970.
16. Kopéc M, ZS Latallo, M Stahl, Z Wegrzynowicz: The effect of proteolytic enzmes on fibrin stabilizing factor. Biochim Biophys Acta 181:437-445, 1969.